Quarterly Earnings

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

In a surprise move, Sun Communities' new CFO is out after less than 30 days. His predecessor steps back in, aiming to calm markets amid a search.

The world's largest jeweler misses 2025 growth targets and issues a sober 2026 forecast, prompting a major strategic shift to platinum-plated jewelry.

Amid strong revenue growth, Capstone's focus on powering AI and datacenters takes center stage as investors await crucial Q3 financial results.

As Aspen Aerogels prepares its Q4 results, investors weigh a challenging 2025 against a booming aerogel market and future EV growth prospects.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

As Erie prepares its 2025 results, investors eye underwriting profit, premium growth, and future guidance in a turbulent insurance market.

With an $80M backlog and a new 'Buy' rating, cybersecurity firm Cycurion looks poised for growth. But can it overcome its volatile past and prove its worth?

PayPal replaces its CEO after just 16 months, bringing in HP's Enrique Lores to combat slowing growth and fierce competition in the digital payments race.

With a challenging year behind them, Hormel's interim leaders will use upcoming events to prove their strategy can restore profitability and win over Wall Street.

With its AI strategy in the spotlight and competitors gaining ground, all eyes are on Cisco's Feb 11 earnings call for signs of growth and future direction.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

From AI brains to spider silk armor, the 'Ironman Economy' is more than a metaphor. But who are the real players and what is the actual investment case?

The analytics giant pays down debt and buys back stock, signaling financial health, but faces analyst skepticism over its long-term growth strategy.

Opera Limited expects to smash Q4 revenue and profit forecasts, crediting its AI-driven strategy and a surge in its high-revenue Western user base.

After its stock plummeted post-IPO, Chinese health-tech firm POMDOCTOR faces a Nasdaq delisting threat, forcing a reckoning with its massive losses.

Tevogen Bio's stock surged on news of a potential special dividend, but a closer look reveals a risky promise from a pre-revenue firm facing major hurdles.